UNSPSC 51283216: Triacetyloleandomycin or troleandomycin

This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but more generally known as triacetyloleandomycin, which bears U.S. National Institutes of Health Compound Identifier 17675. The European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG.

UNSPSC 51283216 Triacetyloleandomycin or troleandomycin is a Commodity code that nominally identifies a specific macrolide antibiotic. Recent state and local procurement activity under this code shows little alignment with the code's stated scope; the opportunities posted are for unrelated pharmaceutical products—doxycycline, ciprofloxacin, and naloxone—suggesting either mislabeling or broad catch-all use of the code by issuing bodies. State and local governments do acquire prescription pharmaceuticals and public-health supplies through piggyback cooperative purchasing vehicles and competitive bidding, but the current record does not demonstrate active demand specifically for triacetyloleandomycin or troleandomycin itself.

Illinois Department of Public Health awarded a completed piggyback contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for doxycycline and ciprofloxacin at $2,999,999.11 over the three-year life of the award; Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building. The mismatch between the code's pharmaceutical specificity and the products actually being solicited suggests this code may not be reliably used by state and local procurement offices for antibiotic purchasing, or that the opportunities have been misclassified. Practitioners pursuing pharmaceutical supply contracts with state and local health agencies should verify the actual UNSPSC coding at the RFQ or IFB stage rather than rely on this code as a reliable signal for opportunity identification.